Challenges With Marketing Mix Modeling in PharmaChallenges With Marketing Mix Modeling in Pharma https://datazymes.com/wp-content/uploads/2021/09/Marketing_Mix-1024x576.jpg 1024 576 deepak https://secure.gravatar.com/avatar/acfa5c400ac94d9a541d4f108658dcbb?s=96&d=mm&r=g
Marketing mix analysis is an ideal way to measure the impact of different marketing channels for various industries, including pharma. The algorithm is quite simple, which further adds to its quick adoption and popularity. It provides us with intuitive, easy-to-explain, and useful results while offering many downstream applications of the channel’s incremental impact. For instance, we can use it to plan a budget, redistribute spend, and maximize ROI. Campaign analysis, sequencing the journey, and next best engagement (NBE) are some of the few projects where the betas can be useful.
Despite being standardized, the marketing mix (MMix) model has a lot of room to grow in the pharma space, such as:
- Large Datasets
The sales and marketing data in the pharma industry can be gigantic. And the longitudinal nature of the marketing mix data can lead to large size of final datasets having millions of rows. To validate the datasets, we need statistical numbers, such as mean, median, percentiles, skew, kurtosis, or graphs.
- We can also use histograms to see the distribution of touchpoints along with scattering plots that can help us select the right transformation while modeling
- Boxplots can help us understand the data distribution and outlier points
- Monthly trends can help us identify the distribution of sales and related activities
But plotting these graphs is computationally expensive. Tools that can quickly process data, such as SAS and SQL, have lower data visualization capability. While the tools that have good visualization features available, like Tableau, Power BI, etc., have a lower computational efficiency.
Another big challenge in marketing mix modeling in pharma is ensuring consistency while using it. Pharma analytics teams are cross-functional, and the results are shared and validated by differet of teams before you can present them to the brand teams for a final review.
The cross-functional nature of the analytics team in pharma prevents easy sharing of the marketing mix results. The context, period, business rules, and other details that were specified during an analysis get lost in translation, and the new team often needs spend additional time in understanding these details. As such there are inherent inefficiencies built into the various steps within the marketing mix.
The data for a traditional MMix is drawn from multiple sources, and these sources have different data formats, refresh frequency, and storage. For example, in pharma, the marketing data may have to be sourced from CRM giants like Veeva or Salesforce, or individual vendors like Doximity and Medscape.
Data gathering requirements differ for cross-functional teams which can result in multiple iterations before the ready-to-use dataset is created. This is caused by the absence of dedicated teams for carrying out specific operations.
After gathering the data, the next step is to check the dataset for errors, missing values, right time frame, right columns, etc., to ensure that the dataset is ready for further use.
In order to verify the business rules for processing the data, the MMix team needs to connect with the brand teams or an onshore counterpart who can be busy at times. Also, identifying the right person to validate the statistics can be time-consuming, which acts as a major roadblock.
Data processing is mostly done manually, leaving a lot of room for errors. The analysts spend a lot of time massaging the data and writing codes but fail to make it error-free. Even a small anomaly that doesn’t look harmful can add investigation time to QC the data, and worse, the error may go undiscovered. For example, if you must sum two columns in SAS and if there are missing values/”.” in a few rows of the data, then the result would be: “.”
Visualization: Because marketing mix projects heavily rely on visual data, plots, and charts to make business decisions, visualization can be challenge due to the limitations of the tools, the computational power, and resources.
Analytics: Since the team only sticks to the most basic visualization, it can result in other downstream challenges, such as a lack of in-depth knowledge about different data properties. It can also lead the team to miss out on the skewness of the data, transformations needed amongst other statistics, which may have to be compensated by running more models.
Insights: Running models is an easy task but generating insights is not. There can be more than a hundred models to run for a given brand. In the absence of any comparative tools to summarize the results, the team has to spend a daunting amount of time in finalizing the results.
Presentation: Building the right story isn’t as easy as it may sound since it requires you to go beyond analytics to derive key insights. Many a time, the brand team doesn’t care about the details about the model and what it means for them, which eventually affects the quality of the presentation.
Marketing mixes were uncommon in the pharmaceutical industry till some years back. Simpler time series and regression models were extensively used. These generate limited insights and cannot glean data concerning marketing expenditures at the granular level. Another critical challenge is related to the integrity of the data as there are multiple overlapping channels that process information simultaneously.
With changing data types and volumes and the growing complexity of marketing channels, a lot of the marketing mix models are changing. Increasingly, a more detailed promotion-response approximation with better accounting dynamics for drug sales and marketing has been carried out in MMixs. Pharma companies want to overcome traditional marketing mix challenges underlined in this blog and capitalize on the most innovative AI and Big Data techniques in user-friendly and operationally efficient ways. Contemporary analytical marketing mixes aim to reduce overall marketing costs while increasing the value of the marketing insights extracted.